TI
CSTL icon

Trexquant Investment’s Castle Biosciences CSTL Stock Holding History

Trexquant Investment’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.92M Buy
206,111
+75,677
+58% +$1.69M 0.03% 757
2026
Q1 		$3.2M Buy
130,434
+65,829
+102% +$2.16M 0.02% 826
2025
Q4 		$2.51M Sell
64,605
-113,837
-64% -$3.67M 0.02% 902
2025
Q3 		$4.06M Sell
178,442
-139,630
-44% -$2.84M 0.04% 627
2025
Q2 		$6.5M Buy
318,072
+69,081
+28% +$1.28M 0.07% 425
2025
Q1 		$4.98M Buy
248,991
+45,420
+22% +$1.12M 0.06% 504
2024
Q4 		$5.43M Buy
203,571
+43,947
+28% +$1.34M 0.06% 499
2024
Q3 		$4.55M Buy
159,624
+116,973
+274% +$2.98M 0.06% 512
2024
Q2 		$929K Sell
42,651
-2,346
-5% -$52.3K 0.01% 1023
2024
Q1 		$997K Buy
44,997
+33,506
+292% +$729K 0.02% 916
2023
Q4 		$248K Sell
11,491
-138
-1% -$2.43K 0.01% 1290
2023
Q3 		$196K Buy
+11,629
New +$203K ﹤0.01% 1345
2022
Q4 		– Sell
-31,616
Closed -$825K – 1423
2022
Q3 		$825K Buy
+31,616
New +$886K 0.03% 601
2021
Q2 		– Sell
-6,982
Closed -$478K – 1157
2021
Q1 		$478K Buy
+6,982
New +$525K 0.04% 528

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trexquant Investment's CSTL Position: Q2 2026 in Review

Trexquant Investment increased its Castle Biosciences (CSTL) stake by 58% in Q2 2026, buying an estimated $1.69M and bringing the position to 206,111 shares worth $4.92M. The position accounts for 0.03% of the portfolio, ranked #757.

Trexquant Investment first reported a position in CSTL in Q1 2021 and has held it in 14 quarters since. The position peaked at $6.5M in Q2 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Trexquant Investment held 206,111 shares of Castle Biosciences worth $4.92M as of Q2 2026.
  • Trexquant Investment bought 75,677 Castle Biosciences shares in Q2 2026, an estimated $1.69M.
  • Castle Biosciences made up 0.03% of Trexquant Investment's portfolio in Q2 2026, its #757 holding.
  • Trexquant Investment first reported a position in Castle Biosciences in Q1 2021 and has held it in 14 quarters since.
  • Trexquant Investment's Castle Biosciences position peaked at $6.5M in Q2 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.